Bedfordshire and Luton Joint Prescribing Committee
Ref: JPC Bulletin 288
Bulletin Date: 26/02/20
Review Date: February 2023
Bulletin 288 Medicinal Cannabis (Sativex®) – a focus on the provision of Sativex® (Cannabis extract) for the treatment of spasticity in patients with Multiple Sclerosis (MS).
The Committee discussed a briefing paper on the above subject and issued the following recommendations:-
To support the use of Sativex®in accordance with NICE Guideline 144, Cannabis-Based Medicinal Products.
- GP prescribing is not recommended at the current time. Discussions are ongoing between the CCGs and secondary care providers regarding provision of Sativex® (including submission of business cases for funding).
- Nabilone for chemotherapy-induced intractable nausea and vomiting is recommended in line with NICE Guideline 144 – Hospital only prescribing.
- NICE supported Cannabidiol with clobazam as an option for treating seizures associated with Dravet syndrome (NICE TA 614) and Lennox-Gastaut syndrome(LGS) (NICE TA 615) in people aged 2 years and older. It was proposed and agreed by the Committee that there should be no GP prescribing as these technologies are commissioned by NHS England and providers are NHS hospitals.
- GP Prescribing of Medicinal Cannabis (licensed or unlicensed) for any other indication is not supported.